To investigate TFPI2's role in sorafenib resistance, we generated sorafenib-resistant HCC cell lines and observed a marked reduction in TFPI2 expression compared to sorafenib-sensitive counterparts (Figure S8A-B). Here, TFPI2 is linked to hepatocellular carcinoma.